source clustersSource Clusters is the single source of information on regional development in the life sciences sector worldwide.

With content providing broad overviews as well as in-depth coverage of business development trends, company activities, life science cluster collaborations, multi-partner scientific projects and its extensive news coverage, Source Clusters presents the latest management, research, technology and regional development information serving the needs of executives in the internationally growing life sciences sector.

Source Clusters is the essential resource for companies, incubators, science parks, clusters and regional development agencies looking to find a new location or attract new business and exploit new opportunities across the life sciences sector.

Owlstone Medical completes $50 million financing

Owlstone person mask 3.11.18Owlstone logo 3.11.18Diagnostics company Owlstone Medical Ltd, which is developing a breathalyser for applications in early disease detection and precision medicine, has completed its financing round to drive the global commercialisation of its Breath Biopsy platform. The round raised a total of $50 million ( about £38 million) inclusive of the previously announced (March 2018) sum of $15 million (about £11 million), bringing the total amount of finance raised by the company to about $73 million (about £56 million) since its founding in 2016.

The initial phase of this financing round was led by Aviva Ventures, the venture capital arm of Aviva plc, a global leader in insurance, and Horizons Ventures, a private investor. The additional $35 million completion of the round was led by Horizons Ventures and a group of global strategic investors that included Ventura Capital and Foxconn Technologies Group.

In this round, Owlstone Medical sought participation from organisations that would be able to provide strategic support for the business in addition to capital investment. With these long-term investors now in place, the company is in a position to benefit from improved access to key markets such as China, to clinical and academic researchers to support product development efforts, to high-quality manufacturing partners, and to additional international funding sources, the company stated.

The funds were raised to expand commercial opportunities in precision medicine, including through the launch of targeted Breath Biopsy kits, and to enable further investment in the technology platform to support the development of additional high-value applications.

For further information about Owlstone Medical visit, for further information about Aviva Ventures visit, for further information about Horizons Ventures visit, for further information about Foxconn Technology Group visit, and for further information about Ventura Capital visit

Last modified onTuesday, 06 November 2018 09:52

Related items

Latest from Tom Mulligan